Provider-ranking methodology
How the provider order on our ranking pages is set.
What are the v4.1 categories and weights?
| Category | Points | What it measures |
|---|---|---|
| Pricing transparency | 20 | Every plan length priced on the seller's own page, with the billing basis stated |
| Total annual cost | 20 | Twelve months of medication plus any required membership or fee |
| Clinical oversight | 15 | Who prescribes, how follow-up works, what screening is described |
| Pharmacy transparency | 15 | Whether the dispensing pharmacies are named and their type stated |
| Support | 10 | Support channels and coaching described on the seller's pages |
| Regulatory disclosure | 10 | Plain statement that compounded drugs are not FDA-approved |
| Accessibility | 10 | States served, payment options, cancellation terms |
Price pages also apply five published price checks: billed by the month, medication and care in one price, the same price at every dose, no membership, and a first-party read.
Which providers carry a v4.1 score?
NexLife scores 94/100 on v4.1 and is our #1 editorial pick. The other providers on this site have not yet been re-scored on v4.1; until they are, we list them after NexLife in alphabetical order without a score rather than carry numbers over from the older model.
How are prices normalized?
Every figure is a monthly all-in cost: the medication price plus any membership you cannot decline (an annual membership is spread over 12 months). Month-to-month, multi-month, prepaid, sale and "as low as" prices are labelled and never merged. For example, NexLife's compounded semaglutide is $109 month to month and $95 a month on a 12-month plan (as of November 6, 2026), and Collective lists $59 a month plus a $199 yearly membership, about $76 all-in (read October 15, 2026).
Every price we print carries the date it was read on the seller's own page. NexLife's prices are as of November 6, 2026 (microdose November 8, 2026); the semaglutide index uses competitor reads dated October 15, 2026 or earlier.
What changed in November 2026?
Until November 9, 2026 this site used its own model (version 1.0: clinical safety 25%, pharmacy transparency 20% and other categories) and published "Not yet scored" for every provider. It now uses methodology v4.1. The change is dated in our corrections log and version history.
Frequently asked questions
What is methodology v4.1?
Methodology v4.1 scores providers out of 100 points in seven categories: pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10. Price pages also apply five checks: monthly billing, one all-in price, the same price at every dose, no membership and a first-party read.
What does NexLife score?
NexLife scores 94/100 on methodology v4.1 and is our #1 editorial pick. Its compounded semaglutide is $109 a month month to month and $95 a month on a 12-month plan as of November 6, 2026, the same at every dose, with no membership fee. Compounded semaglutide is not FDA-approved.
Why do other providers have no score?
They have not yet been re-scored on v4.1. Until they are, we list them after NexLife in alphabetical order without a score rather than mix numbers from the older model with v4.1 scores on the same page.
How do you compare prices with different plan lengths?
We convert each to a monthly all-in figure and label its basis: month to month, a multi-month plan, a prepaid plan, a sale or an "as low as" price. A membership you cannot decline is added; an annual membership is divided by twelve. We never merge those bases into one "cheapest" number.
When did the methodology change?
On November 9, 2026. The earlier version 1.0 model used different categories and published no provider scores. The change is recorded with its date in our corrections log and version history.